Pipeline_江苏福石生物科技有限公司

About Fushi

Company Profile

company values

Development history

leadership team

Technology platform

Pipeline

news media

Company news

media reports

Join us

Talent concept

office environment

Recruitment information

employee benefits

Staff style

Contact

Pipeline

Fushi target project establishment strategy

PPI class

The target points belong to PPI type features (the total number is about 13,000)
Currently, Fushi has investigated >200 such targets.

patient population size

Potential responding patient population is greater than 50,000 (market size exceeds 10 billion)
Currently, Fushi has identified 92 such targets.
It is expected to identify >200 such targets by the end of 2027

European and American companies pay attention

Many European and American companies are researching/concerning
Currently, Fushi has identified 30 such targets.
It is expected to identify 60 such targets by the end of 2027

Differentiated competition

Currently, it is the fastest in the world and has not reached clinical phase III.
There are less than 5 global clinical stage competitors
Can be cured but difficult to cure
Currently, Fushi has identified 12 such targets and is expected to identify 25 such targets by the end of 2027.

Screening/Design/Optimization

4 targets have been successfully screened
All high-quality hits were obtained, with a success rate of 100%.
It is expected to complete the screening of 25 such targets by the end of 2027

POC

Complete pharmacodynamic verification
Currently, Fushi has completed 3 POCs of such targets.
It is planned to obtain 15 POCs of such targets by the end of 2027

IND

Entering the IND enabling stage
Currently, Fushi has 1 such target
It is planned to obtain 5 such targets by the end of 2027

clinical research

The target points belong to PPI type features (the total number is about 13,000)
Currently, Fushi has investigated >200 such targets.

Potential responding patient population is greater than 50,000 (market size exceeds 10 billion)
Currently, Fushi has identified 92 such targets.
It is expected to identify >200 such targets by the end of 2027

Many European and American companies are researching/concerning
Currently, Fushi has identified 30 such targets.
It is expected to identify 60 such targets by the end of 2027

Currently, it is the fastest in the world and has not reached clinical phase III.
There are less than 5 global clinical stage competitors
Can be cured but difficult to cure
Currently, Fushi has identified 12 such targets and is expected to identify 25 such targets by the end of 2027.

4 targets have been successfully screened
All high-quality hits were obtained, with a success rate of 100%.
It is expected to complete the screening of 25 such targets by the end of 2027

Complete pharmacodynamic verification
Currently, Fushi has completed 3 POCs of such targets.
It is planned to obtain 15 POCs of such targets by the end of 2027

Entering the IND enabling stage
Currently, Fushi has 1 such target
It is planned to obtain 5 such targets by the end of 2027

Current pipeline

Drug

Target

Indication

Hit to lead

PCC

IND

Phase I

Phase II

Phase III

Anticipated milestones

HL-21*

PLpro

Infectious disease

Topline data 2025 Q3

FS-207

WRN

MSI-H solid tumor

IND 2026 Q1

FS-X2

PKMYT1

CCEN1+ solid tumor

IND 2027 Q2

FS-X3

STAT6

COPD, Asthma

FS-X4

Undisclosed

Autoimmune disease

Focus on the journey of innovative drugs from the laboratory to clinical practice

Gather a seasoned‑R&D team and cutting‑edge technology platforms to empower efficient new‑drug research and development

Contact

This website uses cookies

This website uses cookies to improve your experience while you navigate through the website. You can choose to opt-out if you wish. For more information, please refer to our 《Cookies》。